PE-22-28
Synthetic peptide studied in animal and cell models for cognitive function enhancement and hippocampal neurogenesis promotion
Last updated: March 1, 2026
- Compound
- PE-22-28
- Class
- Cognitive peptide
- Summary
- Synthetic peptide studied in animal and cell models for cognitive function enhancement, hippocampal neurogenesis promotion, neurotrophic factor upregulation.
- Mechanism
- Serotonergic System Modulation
- Research Status
- Preclinical
- Routes Studied
- Intranasal spray or subcutaneous injection
- Evidence Level
- Preclinical-promising · Clinically unproven
What Should You Know About PE-22-28?
- What is PE-22-28?
- PE-22-28 is a synthetic peptide studied in animal and cell models for cognitive function enhancement and hippocampal neurogenesis promotion.
- Is PE-22-28 clinically proven?
- No. Human evidence remains limited and does not establish PE-22-28 as clinically proven.
- What has PE-22-28 been studied for?
- PE-22-28 has been studied in preclinical models of cognitive function enhancement, hippocampal neurogenesis promotion, neurotrophic factor upregulation. These findings have not been confirmed in large-scale human trials.
- Is PE-22-28 approved?
- No. PE-22-28 is not an approved drug and remains a research compound.
What Is PE-22-28?
PE-22-28 is a synthetic heptapeptide derived from the active region of spadin, itself a natural peptide product of the sortilin propeptide. The compound was first characterized by researchers at the Institut National de la Sante et de la Recherche Medicale (INSERM) in France, who identified it as the minimal active fragment of spadin responsible for inhibiting the TREK-1 potassium channel. TREK-1 (TWIK-related potassium channel 1, also known as KCNK2 or...
Evidence Summary
PE-22-28 has preliminary preclinical evidence only. Human clinical trial data is not available.
Evidence Breakdown
| Domain | Evidence Level |
|---|---|
| Cognitive Function Enhancement | Insufficient |
| Hippocampal Neurogenesis Promotion | Insufficient |
| Neurotrophic Factor Upregulation | Insufficient |
| Serotonergic Tone Enhancement | Insufficient |
| Human clinical evidence | Limited |
| Safety data | Insufficient |
Editorial Position
PE-22-28 is best understood as a preclinical research compound with promising biological signals but limited human validation. Many online claims exceed the strength of available human evidence, and safety data remains incomplete. Any consideration of this compound should involve careful evaluation of individual context and medical guidance.
Regulatory Status Snapshot
- Not approved as a therapeutic drug by major regulators
- Safety profile not established in large human populations
Need help interpreting this evidence for your situation?
Talk to a SpecialistA deep research review for PE-22-28 is not yet available. This compound profile is based on published peer-reviewed references listed below.
Browse all research reviewsWhat Has PE-22-28 Been Studied For?
Research areas where PE-22-28 has been investigated in published studies
-
Cognitive Function Enhancement PE-22-28 has been studied in animal models of cognitive function enhancement. These findings have not been confirmed in controlled human trials.
-
Hippocampal Neurogenesis Promotion PE-22-28 has been studied in animal models of hippocampal neurogenesis promotion. These findings have not been confirmed in controlled human trials.
-
Neurotrophic Factor Upregulation PE-22-28 has been studied in animal models of neurotrophic factor upregulation. These findings have not been confirmed in controlled human trials.
-
Serotonergic Tone Enhancement PE-22-28 has been studied in animal models of serotonergic tone enhancement. These findings have not been confirmed in controlled human trials.
How Does PE-22-28 Work?
These mechanisms have been observed in preclinical models. They are plausible but have not been linked to proven clinical outcomes in humans.
- 01 TREK-1 Channel Antagonism
- 02 Neuronal Depolarization & Excitability Enhancement
- 03 BDNF Upregulation & TrkB Activation
- 04 Physiological outcome
Not sure if PE-22-28 is right for you?
A specialist can review the evidence, evaluate your medical context, and help you make an informed decision about PE-22-28.
Community Reports (Anecdotal)
Experiences shared here are self-reported and do not represent clinical evidence.
Rate PE-22-28
How Is PE-22-28 Administered?
PE-22-28 is available via Intranasal spray or subcutaneous injection. Appropriate use and protocol should be determined by a qualified specialist.
What Are the Specifications of PE-22-28?
What Conditions Has PE-22-28 Been Linked To?
Have Questions About PE-22-28?
TREK-1 channels maintain a background potassium leak current that hyperpolarizes neurons, reducing their excitability. By blocking this current, PE-22-28 mildly depolarizes neurons in the hippocampus and prefrontal cortex, enhancing their responsiveness to synaptic inputs.
Published studies on PE-22-28 can be found on PubMed and other peer-reviewed databases. Our references section below lists key citations.
PE-22-28 is available as a research compound in Thailand. Consult a qualified specialist to discuss whether it is appropriate for your needs.
Ready to discuss PE-22-28 with a specialist?
Get evidence-based guidance tailored to your health goals and medical context.
Book a Consultation Free initial consultation. No obligation.Reviewed by the Peptide Science Thailand Editorial Team.
Last reviewed: March 1, 2026